Clinical Anslysis of Primary Adrenal NK/T-Cell Lymphoma / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 396-402, 2023.
Article
de Zh
| WPRIM
| ID: wpr-982072
Bibliothèque responsable:
WPRO
ABSTRACT
OBJECTIVE@#To investigate the clinical characteristics, diagnosis, and treatment of one patient with primary adrenal natural killer/T-cell lymphoma (PANKTCL), and to strengthen the understanding of this rare type of lymphoma.@*METHODS@#The clinical manifestations, diagnosis and treatment process, and prognosis of the patient admitted in our hospital were retrospectively analyzed.@*RESULTS@#Combined with pathology, imaging, bone marrow examination, etc, the patient was diagnosed with PANKTCL (CA stage, stage II; PINK-E score 3, high-risk group). Six cycles of "P-GemOx+VP-16" regimen(gemcitabine 1 g/m2 d1 + oxaliplatin 100 mg/m2 d 1 + etoposide 60 mg/m2 d 2-4 + polyethylene glycol conjugated asparaginase 3 750 IU d 5) was performed, and complete response was assessed in 4 cycles. Maintenance therapy with sintilimab was administered after the completion of chemotherapy. Eight months after the complete response, the patient experienced disease recurrence and underwent a total of four courses of chemotherapy, during which hemophagocytic syndrome occurred. The patient died of disease progression 1 month later.@*CONCLUSION@#PANKTCL is rare, relapses easily, and has a worse prognosis. The choice of the "P-GemOx+VP-16" regimen combined with sintilimab help to improve the survival prognosis of patient with non-upper aerodigestive tract natural killer /T-cell lymphoma.
Mots clés
Texte intégral:
1
Base de données:
WPRIM
Sujet principal:
Asparaginase
/
Protocoles de polychimiothérapie antinéoplasique
/
Études rétrospectives
/
Lymphome T périphérique
/
Résultat thérapeutique
/
Désoxycytidine
/
Étoposide
/
Lymphome T-NK extraganglionnaire
/
Oxaliplatine
/
Récidive tumorale locale
Limites:
Humans
Langue:
Zh
Journal:
Journal of Experimental Hematology
Année:
2023
Type de document:
Article